Skip to content

Drug interactions

Bosentan + Pralsetinib

Severity: Moderate

Bosentan and Pralsetinib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Pralsetinib is a CYP3A4 substrate, so induction by bosentan may reduce its concentrations and anticancer efficacy.

What this interaction means in plain words

Bosentan and Pralsetinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Bosentan belongs to Miscellaneous; Pralsetinib belongs to Oncology.

Evidence level: Moderate

Why it happens

Bosentan induces CYP3A4, increasing pralsetinib clearance.

What to do

Avoid if possible. If unavoidable, follow labeling to increase the pralsetinib dose and monitor tumor response.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Bosentan and Pralsetinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Bosentan with Pralsetinib?

MediHelp rates the interaction as moderate. Bosentan and Pralsetinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Pralsetinib is a CYP3A4 substrate, so induction by bosentan may reduce its concentrations and anticancer efficacy.

How serious is the interaction between Bosentan and Pralsetinib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid if possible. If unavoidable, follow labeling to increase the pralsetinib dose and monitor tumor response.

What other medicines interact with Bosentan?

MediHelp also lists interactions of Bosentan with, for example, Cyclosporin, Glibenclamide, Glyburide-metformin. The full list is on the Bosentan page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in